Regeneron Pharmaceuticals (REGN) Operating Expenses (2009 - 2026)

Regeneron Pharmaceuticals' Operating Expenses history runs 18 years deep, the most recent figure standing at $3.0 billion for Q1 2026.

• In Q1 2026, Operating Expenses rose 21.56% year-over-year to $3.0 billion; the TTM figure through Mar 2026 stood at $11.3 billion (up 10.1% YoY), while the FY2025 annual figure was $10.8 billion, up 5.42% from the prior year.
• Operating Expenses was $3.0 billion for Q1 2026 at Regeneron Pharmaceuticals, down from $3.0 billion in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $3.0 billion in Q4 2025 to a low of $1.7 billion in Q1 2022.
• Historically, Operating Expenses has averaged $2.4 billion across 5 years, with a median of $2.4 billion in 2025.
• The sharpest annual moves came in 2022 and 2023: Operating Expenses decreased 2.46% in 2022, then surged 31.49% in 2023.
• A 5-year view of Operating Expenses shows it stood at $2.3 billion in 2022, then advanced by 8.55% to $2.5 billion in 2023, then advanced by 13.72% to $2.8 billion in 2024, then climbed by 7.34% to $3.0 billion in 2025, then fell by 1.39% to $3.0 billion in 2026.
• The last three Operating Expenses figures came in at $3.0 billion (Q1 2026), $3.0 billion (Q4 2025), and $2.7 billion (Q3 2025), per Business Quant data.